Syngene is excited to announce its participation in CPHI Japan 2024. The event will be held at Tokyo Big Sight from 17-19 April 2024.
As a full-service provider, leading contract research organisation (CRO) and contract development and manufacturing organisation (CDMO), Syngene offers integrated discovery, development and manufacturing services across small molecules and biologics. The company specialises in a range of clinical development solutions, including bioequivalence studies (BA/BE), Phase-1 studies for biosimilars or vaccines, Phase I-IV trials in patient populations, and regulated bioanalytical support for small and large molecule development programmes.
Outsourcing clinical requirements to Syngene presents numerous advantages, including access to a larger pool of volunteers/patients for quicker recruitment, efficient regulatory processes ensuring timely approvals and study conduct, and timely project execution facilitated by experienced teams and facilities.
Attendees of CPHI Japan 2024 are encouraged to visit Booth #4W-33 to meet the Syngene team and explore how the company can accelerate their clinical development programmes. To schedule a meeting, please contact bdc@syngeneintl.com.